CannPal’s medicinal cannabis pet product show successful study results



CannPal (ASX: CP1) recently presented Phase I research results for their dog product CPAT-01, to treat pain and control inflammation, at the 2019 Australian Veterinary Association Innovation, Research and Development Symposium. T

The study compared a high-THC, low-CBD product, a high-CBD, low-CBD product and a placebo in 11 healthy dogs to determine safety and assess pharmacology.

Results showed no adverse effects or psychotropic changes in any of the dogs, and suggested that THC and CBD have the potential to control pain and inflammation in dogs.

This research is to be published in the Australian Veterinary Journal, Australia’s premier veterinary scientific journal.

The next step for CannPal is to test these products on dogs suffering from pain and inflammation to determine efficacy.

CannPal’s Head of Research and Development, Dr Margaret Curtis, said “The Innovation Symposium was a fantastic opportunity to showcase the breadth and depth of CannPal’s research to the veterinary fraternity in Australia. It was a pleasure to share some of the exciting data that CannPal is generating with the wider scientific community, which we believe can help contribute to the advancement of cannabinoid derived therapeutic research across all species.”

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”